HA NOI, April 17, 2024, Pfizer Vietnam has signed a Memorandum of Understanding (MOU) in cooperation with the Vietnam Medical Association (VMA) to jointly implement a number of projects in healthcare.

 Photo: Pfizer Vietnam and Vietnam Medical Association (VMA) at the signing ceremony

This cooperation aims to enhance the effectiveness of antimicrobial resistance management, an important task of healthcare sector as mentioned in the National Strategy on Antimicrobial Resistance Control 2023 – 2030, with a vision to 2045. It builds on Pfizer's expertise in pharmaceuticals and its relevant resources, along with the VMA's close engagement and deep understanding of the role and responsibility of hospitals and government management units in the fight against this recent growing threat of antimicrobial resistance.

Following the Covid-19 pandemic, the collaborative efforts between prevention and treatment in managing respiratory diseases has emerged as a priority.  Together, Pfizer Vietnam and the VMA have committed to providing expertise and resources each other to enhance opportunity for patient to access to new prevention solutions and new medicines for management of respiratory infections.

In addition, both parties have also committed to continuing cooperation, exchange, and support in updating medical information and knowledge for healthcare professionals. This is important in enhancing the healthcare capability of healthcare professionals to ensure the health welfare of the Vietnamese people.

In order to achieve the above mutual aligned goals, the project is designed to enhance healthcare outcomes through a series of joint initiatives, including:

• Collaboration in support and sponsor scientific activities about relevant scientific information in healthcare and health policy/management.
• Collaborate with relevant healthcare organizations to support the hospital sector in implementing the antimicrobial resistance management program- AMS, thus enhancing the capability of clinical microbiology, clinical pharmacology and clinician in appropriate use of antibiotics
• Collaborate with relevant organizations to enhance the prevention, diagnosis, and treatment capability of respiratory diseases.

Assoc.Prof.PhD.MD Nguyen Thi Xuyen, President of VMA stated, The Memorandum of Understanding with Pfizer Vietnam marks a milestone in the cooperation between stakeholders for jointly improving the quality of healthcare for the people. We hope to bring positive impacts from our joint initiatives through the specific programs mentioned.”

Anil Argilla, Pfizer President EM Asia said, “The collaborative partnership between Pfizer and the Vietnam Medical Association is a testament to Pfizer's commitment to social and community responsibility. It plays an important role in enhancing health system efficiency and patient care.”

“We are delighted to partner with the Vietnam Medical Association to address critical healthcare challenges in Vietnam," said Darrell Oh, General Director of Pfizer Vietnam. "Both AMR and respiratory illnesses are of immediate concern to society at large and I believe that these efforts will yield tangible benefits in both governance and patient health.”

About Pfizer: Breakthroughs That Change Patients’ Lives 
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. 

Disclosure Notice 
The information contained in this release is as of April 17, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Media Contact
Minh Ha Ho
+84 987 530 219
[email protected]